{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:40:10Z","timestamp":1756798810225,"version":"3.44.0"},"reference-count":13,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A modified controlled\u2010release sodium valproate formulation (VAL001, test) was compared with an approved enteric\u2010coated tablet formulation (Absenor, reference). Pharmacokinetics and safety\/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early\u2010phase patient trial of valproate in combination with chemotherapy in diffuse large B\u2010cell lymphoma. In Part I (n\u00a0=\u00a012), both formulations were administered as single doses (30\u00a0mg\/kg) in a randomized crossover fashion. Equivalent exposures (area under the plasma concentration\u2013time curve) for total and free valproate were observed under fasted conditions. Intake with food delayed the absorption of valproate from the test formulation, with no impact on AUC. In Part II (n\u00a0=\u00a027), both formulations were administered over 3 consecutive days, at 30\u00a0mg\/kg twice daily (test) or 20\u00a0mg\/kg 3 times daily (reference). Similar steady\u2010state levels were observed, but fluctuation was less with the test product (23% vs. 47%, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.0102). Inhibition of histone deacetylase activity was evidenced by increased levels of acetylated H3K9 in peripheral blood mononuclear cells. No serious or severe adverse events were observed. The novel capsule formulation of valproate, containing a combination of immediate\u2010release granules and extended\u2010release pellets, appears to have suitable pharmacokinetic properties for cancer treatments aiming for histone deacetylase inhibition.<\/jats:p>","DOI":"10.1002\/cpdd.1555","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:51:31Z","timestamp":1748353891000},"page":"717-727","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Immediate\u2010Release and Extended\u2010Release Formulation of Sodium Valproate Provides Stable Plasma Levels for Inhibition of Histone Deacetylation"],"prefix":"10.1002","volume":"14","author":[{"given":"Nikhil","family":"Ahuja","sequence":"first","affiliation":[{"name":"Clinical Research Services Turku, CRST Oy  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"K\u00e4\u00e4ri\u00e4inen","sequence":"additional","affiliation":[{"name":"Clinical Research Services Turku, CRST Oy  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Lovr\u00f3","sequence":"additional","affiliation":[{"name":"Clinical Research Services Turku, CRST Oy  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Lundblad","sequence":"additional","affiliation":[{"name":"Valcuria AB (wholly owned subsidiary of Respiratorius AB)  Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Drott","sequence":"additional","affiliation":[{"name":"Valcuria AB (wholly owned subsidiary of Respiratorius AB)  Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Lilienberg","sequence":"additional","affiliation":[{"name":"SDS Life Science AB (part of Cytel Inc.)  Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica T.","family":"Engstr\u00f6m","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine University of Turku  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Saukkonen","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine University of Turku  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Scheinin","sequence":"additional","affiliation":[{"name":"Clinical Research Services Turku, CRST Oy  Finland"},{"name":"Institute of Biomedicine University of Turku  Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.24.6969"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21132"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0031"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0026-8"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0079"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.6165"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1930"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-4-4"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019240"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2089"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.12.004"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T07:14:10Z","timestamp":1756797250000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cpdd.1555"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1555","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}